Other formats:
BibTeX
LaTeX
RIS
@article{1792166, author = {Mahdal, Michal and Neradil, Jakub and Múdry, Peter and Paukovčeková, Silvia and Zambo, Iva and Urban, Jiří and Macsek, Peter and Pazourek, Lukáš and Tomáš, Tomáš and Veselská, Renata}, article_location = {Basel}, article_number = {14}, doi = {http://dx.doi.org/10.3390/cancers13143543}, keywords = {giant-cell tumor of bone; targeted treatment; sunitinib; PDGFR beta; denosumab; signaling}, language = {eng}, issn = {2072-6694}, journal = {Cancers}, title = {New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling}, url = {https://www.mdpi.com/2072-6694/13/14/3543}, volume = {13}, year = {2021} }
TY - JOUR ID - 1792166 AU - Mahdal, Michal - Neradil, Jakub - Múdry, Peter - Paukovčeková, Silvia - Zambo, Iva - Urban, Jiří - Macsek, Peter - Pazourek, Lukáš - Tomáš, Tomáš - Veselská, Renata PY - 2021 TI - New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling JF - Cancers VL - 13 IS - 14 SP - 3543 EP - 3543 PB - MDPI SN - 20726694 KW - giant-cell tumor of bone KW - targeted treatment KW - sunitinib KW - PDGFR beta KW - denosumab KW - signaling UR - https://www.mdpi.com/2072-6694/13/14/3543 N2 - The purpose of this study was to analyze differential cell signaling in response to denosumab treatment to identify and subsequently inhibit molecular targets in the neoplastic stromal cell population, which poses a risk for tumor recurrence. Using phosphoprotein arrays, a distinct signaling profile was detected in GCTB tissues treated with denosumab, a specific RANKL antibody, which coincided with the RTK profile in derived cell lines. PDGFRβ was selected as a promising receptor target, and its inhibition by the small-molecule inhibitor sunitinib resulted in potent inhibition of cell proliferation in vitro. The addition of sunitinib to denosumab resulted in the disappearance of both multinuclear giant cells and neoplastic stromal cells, as reported here. Thus, sunitinib could become an effective addition to denosumab in the treatment of GCTB with activated PDGFRβ. ER -
MAHDAL, Michal, Jakub NERADIL, Peter MÚDRY, Silvia PAUKOVČEKOVÁ, Iva ZAMBO, Jiří URBAN, Peter MACSEK, Lukáš PAZOUREK, Tomáš TOMÁŠ and Renata VESELSKÁ. New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling. \textit{Cancers}. Basel: MDPI, 2021, vol.~13, No~14, p.~3543-3557. ISSN~2072-6694. Available from: https://dx.doi.org/10.3390/cancers13143543.
|